{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-107438","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.284428+00:00","generated_at":"2026-05-16T23:51:33.714283+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Replimune reports Q2 net loss $83.1M; FDA accepts RP1 BLA resubmission with PDUFA April 10, 2026","bullets":["Cash, equivalents and investments $323.6M at Sep 30, 2025, down from $483.8M at Mar 31, 2025.","R&D expenses $57.9M vs $43.4M YoY; S,G&A $26.4M vs $15.5M YoY.","Net loss $83.1M vs $53.1M in prior year quarter.","FDA accepted BLA resubmission for RP1 in advanced melanoma; PDUFA target action date April 10, 2026.","Phase 3 IGNYTE-3 trial enrolling ~400 patients; REVEAL Phase 2/3 for RP2 in uveal melanoma enrolling."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-107438","json":"https://secwatch.observer/filing/0001104659-25-107438.json","markdown":"https://secwatch.observer/filing/0001104659-25-107438.md","text":"https://secwatch.observer/filing/0001104659-25-107438.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465925107438/0001104659-25-107438-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465925107438/tm2530417d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:51:33.714283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}